Email ID : 
Password : 
Forgot Your Password ? 

Only Report Titles
Titles & Keywords
NOTE: Site best viewed with Internet Explorer
  AUTOMATED AND RAPID MICROBIOLOGICAL TESTS
A Global Strategic Business Report

This report analyzes the worldwide markets for Automated and Rapid Microbiological Tests in Millions of US$. The Major End-Use Segments Analyzed are Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, & Other Automated & Rapid Microbiological Tests), and Non-Clinical Applications. The report provides separate comprehensive analytics for the US, Europe, and Rest of World. Annual forecasts are provided for each region for the period of 2000 through 2015. The report profiles 127 companies including many key and niche players worldwide such as Abbott Laboratories, Abbott Diagnostics, Becton Dickinson and Company, bioMerieux, bioMerieux, Inc., Bio-Rad Laboratories, Cellabs Pty Ltd, Celsis International Plc., Coris BioConcept, F. Hoffmann-La Roche Ltd., Gen-Probe Incorporated, Genzyme Diagnostics, Inverness Medical Innovations, Inc., Unipath Limited, MedMira Inc., Meridian Biosciences, Inc., Orasure Technologies, Inc., Orion Diagnostica Oy, Quidel Corporation, Siemens Medical Solutions Diagnostics, Thermo Fisher Scientific, Inc., Remel, Inc., and Oxoid Limited. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

CODE:    MCP-1093  PAGES:    619
PRICE:    $3950  DATE:       May 2008
COMPANIES:  127  MARKET DATA TABLES:   197
Due to the proprietary nature, our previews are offered only to manufacturers, top-tier management consultants, investment banks, and investment research groups.

 TABLE OF CONTENTS  
  AUTOMATED AND RAPID MICROBIOLOGICAL TESTS (Complete Report) Pages : 619   | $3950
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS5$100
   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Quantitative Techniques & Analytics.....I-3
Product Definitions and Scope of Study.....I-3
Automated and Rapid Microbiological Tests: A Definition.....I-3
  
   Clinical Applications.....I-4
Automated Identification and Susceptibility Systems.....I-4
Automated Blood Culture Systems.....I-4
Automated Tuberculosis Systems.....I-4
Streptococcal Infection Rapid Tests.....I-4
GC/Chlamydia Rapid Tests.....I-4
  
   Other Automated & Rapid Microbiological Tests.....I-5
Non-Clinical Applications.....I-5
  
II. EXECUTIVE SUMMARY115$2250
  1. Industry Overview.....II-19 $800  
   Outlook.....II-1
Evolutionary Battle Against the Bugs Drives the Future of the Market .....II-1
Automated Microbiological Tests: A Pesky Gray Area in the Clinical Diagnostics
  Market.....II-1
1$100
   Traditional Rapid Microbiological Tests Destined to Go Out With the Old.....II-2
A Current & Future Analysis.....II-2
1$100
   Segmental Perspective.....II-3
Clinical Applications.....II-3
Non-Clinical Applications.....II-3
Macro: The Big Picture.....II-3
1$100
   Deciding the Market’s Future .....II-4
A Holistic Peek into a Few Noteworthy Trends.....II-4
1$100
   Biotechnology & Rapid Microbial Tests.....II-5
Automated & Rapid Microbiological Tests: “Current Market Stance”.....II-5
1$100
   A Business Case for Automated & Rapid Microbiological Testing.....II-6
Near Patient Testing: An Offshoot of Rapid Microbiological Tests.....II-6
1$100
   Pros & Cons of Near Patient Testing.....II-7
Role of Near Patient Testing in Reducing Antibiotic Resistance in Humans.....II-7
1$100
   The Pre/Post Microbial Rapid Testing Era: A Review.....II-8
Market Structure.....II-8
Competitive Setup of the Diverse Automated & Rapid Microbiology Products
  Market.....II-8
1$100
   Historic Data.....II-9
Table 1: Leading Players in World Market for IVD Automated Microbiology Systems (2000) - Percentage Breakdown of Value Sales by Company forbioMerieux, Dade Behring, Becton Dickinson,Organon Teknika, and Others (includescorresponding Graph/Chart).....II-9
1$300
  2. Trends & Issues.....II-109 $600  
   Advancements in Molecular Diagnostics - A Boon or a Threat.....II-10
Antibiotic Resistant Bacteria Throws the Spotlight On Microbial Testing.....II-10
1$100
   Instant Detection of Pathogens – A New Epoch in the Fight for Survival.....II-11
Lower Cost Rapid Tests Built on Multiple Sampling Modalities – Gaining
  Momentum.....II-11
“Time Constraints?” - Rapid Tests to the Rescue.....II-11
1$100
   Rapid HIV Tests: A New Age Diagnostic Weapon Against the Killer Disease.....II-12
Accuracy/Reliability of Home HIV Testing: A Bone of Contention.....II-12
1$100
   Development of Near Patient Test Kits: A Market Driven Phenomenon.....II-13
Near Patient Test Kits: A Rumination of Possibilities.....II-13
Automated Blood Culture Systems: A Winning Edge in the Fight Against
  Bacteremia.....II-13
1$100
   Leading Food Processors Resort to Rapid Microbiological Testing.....II-141$100
   Impact of Food Scares on Rapid Microbiological Tests Market.....II-15
Demand for Microbiological Tests & Level of QC in the Food Industry.....II-15
1$100
   Rapid Tests Creating Brighter Avenues in Food Microbiology Testing Market.....II-16
Dire Need to Nip Operating Costs Throws the Spotlight on Rapid Tests.....II-16
1$100
   Key Advantages/Benefits of Rapid Microbiological Tests on Food.....II-17
Food Packages of the Future Ingrained with Microbial Alert Systems.....II-17
Technology Innovations in Rapid Food Microbial Testing.....II-17
1$100
   Obtaining Regulatory Approval – A Major Non-Technical Hindrance.....II-18
1$100
  3. Factors Influencing the Market.....II-194 $400  
   Continuing Biological Warfare with Pathogens Sparks Market Growth .....II-19
Innovative Products – A Key Growth Strategy.....II-19
Other Market Drivers in a Capsule.....II-19
Low Turnaround Times Skyrocket Demand.....II-19
Greater Patient Awareness.....II-19
1$100
   Rising Incidence of STDs Kindles Universal Market Acceptance.....II-20
Ultra-Rapid HIV-Screening Tests- A Strong Fight against HIV-Epidemic.....II-20
Validation of Rapid Microbiological Tests: An Imperative Prerequisite.....II-20
1$100
   Non-Conformance to Testing Requirements: A Weighty Concern.....II-21
Influenza – Boosting Rapid Test Prospects.....II-21
2$200
  4. Product/Technology Overview.....II-2310 $700  
   Automated & Rapid Microbiological Tests: A Definition.....II-23
Benefits of Automated & Rapid Microbiological Tests.....II-23
1$100
   Classification of Rapid Microbiological Test Methods.....II-24
How Does a Rapid Test Work?.....II-24
1$100
   Sample Preparation – A Key Procedure.....II-25
Automated Identification and Susceptibility Systems.....II-25
Automated Blood Culture Systems.....II-25
1$100
   Automated Tuberculosis Systems.....II-26
Microminiaturization of Diagnostic Tests: How Is It Effected?.....II-26
Advantages of Microminiaturisation:.....II-26
1$100
   Acid-Fast Microscopy – The Forerunner of Rapid Tests.....II-27
Gram's Stain: A Time-Honored & Rapid Method to Detect Pathogens in Blood.....II-27
1$100
   Enabling Technologies of Automated & Rapid Microbiological Tests.....II-28
Growth-based Technologies.....II-28
Viability-based Technologies.....II-28
Cellular-Component or Artifact-based Technologies.....II-28
Genomics/ Proteomics.....II-28
1$100
   Microarrays/ Microfluidics.....II-29
DNA Microchips/Probes.....II-29
1$100
   Polymerase Chain Reaction (PCR).....II-30
Immunoassay.....II-30
Immunoassay Escalates into Diverse Fields of Diagnostic Testing.....II-30
1$100
   Nucleic Acid Testing (NAT).....II-31
Nucleic Acid Probes.....II-31
Signal-Amplified Tests.....II-31
Nucleic Acid Amplification Tests.....II-31
1$100
   Traditional Methods with Computer-Aided Imaging.....II-32
Combination Methods.....II-32
1$100
  5. End-Use Application Analysis.....II-3311 $700  
   Applications in Clinical Investigations.....II-33
STD Rapid Tests.....II-33
GC/Chlamydia Rapid Tests.....II-33
1$100
   HIV Rapid Tests.....II-34
HIV Facts & Figures.....II-34
1$100
   Advantages of Rapid HIV Testing.....II-35
Disadvantages of Rapid HIV Testing.....II-35
1$100
   Syphilis Rapid Tests.....II-36
Respiratory Rapid Tests.....II-36
RSV/ Influenza Rapid Tests.....II-36
1$100
   Tuberculosis Rapid Tests.....II-37
Group A beta Hemolytic Streptococcus Rapid Tests.....II-37
Mononucleosis Rapid Tests.....II-37
Streptococcus Rapid Tests.....II-37
1$100
   Streptococcus A Rapid Tests.....II-38
Streptococcus B Rapid Tests.....II-38
1$100
   Gastrointestinal Rapid Tests.....II-39
Giardia Lamblia Rapid Tests.....II-39
H. Pylori Rapid Tests.....II-39
Cryptosporidium Rapid Tests.....II-39
1$100
   C. Difficile Rapid Tests.....II-40
Applications in Non-Clinical Investigations.....II-40
Food/Water Safety Tests.....II-40
1$100
   Food Safety Testing: A Lucrative Application Area.....II-41
Rapid Microbiological Methods in Pharmaceutical Sector.....II-41
1$100
   Limitations of RMMs.....II-42
Advantages of RMMs.....II-42
Applications in Pharmaceutical Sector.....II-42
1$100
   Environmental Tests.....II-43
Other Miscellaneous Applications.....II-43
1$100
  6. Product Innovations/Introductions.....II-4412 $800  
   Meridian Bioscience Rolls Out Two New Rapid Tests for Detecting Epstein-Barr
  Virus.....II-44
Oxoid Introduces Staph Plus System for Identifying Staphylococcal Species.....II-44
Siemens Healthcare Diagnostics Launches MicroScan® WalkAway® plus Diagnostic
  Microbiology Systems.....II-44
Bio-Rad Launches a Rapid test for Screening MRSA, MRSASelect™ test, in US.....II-44
1$100
   bioMérieux Introduces VIDAS®, an automated Clostridium difficile A & B Toxins
  Detection Test.....II-45
Oxoid Launches Remel Wellcolex® Colour Tests for Testing Shigella, E. coli O157 and
  Salmonella.....II-45
Siemens Healthcare Diagnostics Obtains Health Canada Approval for its VERSANT 440
  Molecular System .....II-45
1$100
   Oxoid Unveils Remel Xpect™ Clostridium Difficile Toxin A/B Test .....II-46
Neogen Introduces Soleris System.....II-46
ATCC Introduces Authenticult™ Quality Control Microbiological Testing Tool.....II-46
Bio-Rad Introduces New EBV Kits.....II-46
Roche Seeks FDA Marketing Approval for Hepatitis C Virus Test.....II-46
1$100
   Roche Seeks US FDA Approval for its Cobas TaqScreen MPX Test.....II-47
FDA Clears Usage of TIGRIS® System for Testing WNV in Donated Blood.....II-47
FDA Approves ImmunoCard STAT!® EHEC for Detecting E. coli Infection.....II-47
bioMérieux Introduces TEMPO® Quality Indicator Testing System.....II-47
1$100
   Biotrace Introduces Tecra Unique Campylobacter Rapid Test.....II-48
bioMérieux Introduces TEMPO® EB test for Enterobacteriaceae.....II-48
Roche Unveils Elecsys TORCH Assays.....II-48
Roche Diagnostics Introduces Cobas TaqMan MTB Test in Japan.....II-48
bioMérieux Develops Advanced Colorimetry™ NH Card.....II-48
1$100
   Roche Introduces Rapid LightCycler SeptiFast Sepsis Test across EU.....II-49
Oxoid Launches New Rapid Test for Salmonella Detection in Food Products.....II-49
Oxoid Unveils New Contact Plate Design.....II-49
FDA Approves Fluconazole Susceptibility Tests from BioMérieux.....II-49
1$100
   Polysciences Unveils New Microbiological & Bacterial Detection Applications.....II-50
Researchers Develop New Rapid MODS Test for TB Detection.....II-50
Dade Behring Unveils Automated Quadriga BeFree System.....II-50
FDA Approves Abbott PRISM® HBsAg Assay.....II-50
1$100
   Bayer’s EHIV Test Receives FDA Clearance.....II-51
Gen-Probe Obtains FDA Approval to Use Aptima Test on Additional Specimens.....II-51
Roche Diagnostics’ cobas TaqScreen MPX Test Receives CE Mark Approval.....II-51
Cepheid Introduces Rapid Xpert® MRSA Test in Europe.....II-51
Bio-Rad Widens Culture Media with Addition of RAPID'Salmonella.....II-51
1$100
   Chemogen Develops New Tuberculosis Rapid Test.....II-52
bioMerieux Rolls Out VIDAS® LDUO Test.....II-52
Zonda Develops New Rapid Test for Chlamydia.....II-52
MedMira Launches MiraCare Rapid HIV Test.....II-52
STMicroelectronics and Mobidiag Unveil Lab-On-Chip.....II-52
1$100
   Vermicon Launches ScanVIT-Legionella Rapid Test Kit.....II-53
New Line of Rapid Microbial Detection Systems from Centrus.....II-53
OraSure Rolls Out OraQuick ADVANCE.....II-53
Abbott Unveils Automated HCV Test.....II-53
ViroMed Rolls Out Rapid PCR Tests for Detecting Influenza and Respiratory
  Pathogens.....II-53
Biophage Pharma Offers Service for Microbiological Testing.....II-53
1$100
   bioMerieux Releases New Rapid Test for Nosocomial Infections.....II-54
bioMerieux Widens Product Portfolio with Addition of TEMPO® System.....II-54
Celsis Introduces CellScan Innovate Rapid Screening System.....II-54
Millipore Rolls Out Rapid Microbiology Detection System.....II-54
Calypte Biomedical Develops Oral Fluid Rapid Test for HIV- 1/2.....II-54
1$100
   BioMerieux Unveils VITEK® 2 Compact.....II-55
Bio-Rad Unveils New Test Kits and Comprehensive Automated Systems.....II-55
1$100
  7. Recent Industry Activity.....II-5622 $1200  
   Becton, Dickinson Establishes New Rapid Diagnostic Products Manufacturing Facility in
  China.....II-56
Quidel Corporation Obtains CLIA Waiver from US FDA for its QuickVue(R) RSV
  Test.....II-56
Siemens Obtains US FDA Approval for its VERSANT™ 440 Molecular System.....II-56
bioMérieux to Market Wescor’s Customized Slide Stainer Instruments under bioMérieux
  Brand.....II-56
1$100
   Schering-Plough and OraSure Ink Collaboration Agreement for Developing Rapid Oral HCV
  Test.....II-57
Abbott Obtains US FDA Approval for its Automated HTLV-I/HTLV-II Blood Screening
  Test.....II-57
Quidel and bioMérieux Form a Long-term Alliance in Rapid Diagnostic Tests.....II-57
BD Diagnostics Obtains US FDA Approval BD GeneOhm™ StaphSR assay.....II-57
1$100
   Meridian Bioscience Obtains US FDA Approval for Two New Rapid Tests.....II-58
Siemens AG Acquires Dade Behring.....II-58
Thermo Fisher Scientific Teams Up with KBA for Expanding its Microbiology Business
  Division in Lenexa.....II-58
OraSure and SCMS Enter into an Agreement for Supplying OraQuick(R) HIV Test to PEPFAR
  Countries.....II-58
1$100
   Abbott Obtains US FDA Approval for its Fully Automated PRISM® HCV Test.....II-59
Gen-Probe Obtains US FDA Approval for its PROCLEIX® TIGRIS® System for Testing Donated
  Blood.....II-59
AdvanDx Ropes In bioMérieux for Distributing its Rapid Diagnostic Tests in US.....II-59
3M and Gen-Probe Join Hands to Develop Rapid Molecular Tests For Detecting
  HAIs.....II-59
1$100
   Gen-Probe’s PROCLEIX® TIGRIS® System Obtains US FDA Approval for Screening Donated
  Blood for West Nile Virus .....II-60
3M Acquires Acolyte Biomedica.....II-60
1$100
   Formation of Siemens Medical Solutions Diagnostics.....II-61
bioMérieux Bags Contract to Provide VITEK® 2 System for Scottish NHS Labs.....II-61
bioMérieux Licenses NorChip’s HPV Test Technology for Cervical Cancer.....II-61
1$100
   bioMérieux in Strategic Agreement with Cepheid for Sepsis Assays.....II-62
3M Health Care Creates New Medical Diagnostics Unit.....II-62
Schering-Plough & OraSure to Develop Rapid Oral HCV Test.....II-62
3M Acquires Biotrace International.....II-62
1$100
   Siemens Acquires DPC.....II-63
Oxoid Acquires Microbiology Business Activities of Dako.....II-63
Inverness Acquires IDT and Thermo BioStar.....II-63
1$100
   BMD in Agreement with MND for Research on Diagnostic Tests.....II-64
Cepheid Wins CDC Contract to Develop Rapid Bird Flu Virus Detection Test.....II-64
Dutch Government Grants €7.9 Million to FIND.....II-64
1$100
   FIND and Hain to Develop Rapid Test for MDR and XDR TB.....II-65
3M & Gen-Probe Ally for Developing Rapid Molecular Tests for Food Safety.....II-65
Bio View Inks Three-Year Distribution Agreement with Abbott Molecular.....II-65
1$100
   Bodycote Acquires Foodscan Laboratories.....II-66
Cepheid Bags STTR Funding for Development of Rapid TB Test.....II-66
Abbott and Verax in Distribution Agreement for Verax Platelet PGD® Test.....II-66
BSL Supplies ABBOTT PRISM® System to Blood Donor Testing Centers.....II-66
1$100
   Abbott & ARC in Agreement for Automated Blood Screening Tests.....II-67
BD to Set Up Production Facility for Rapid Diagnostic Products in China.....II-67
BD Diagnostics Delivers STI Testing Products to BioReference.....II-67
Meridian Licenses LAMP Diagnostic Test Technology from Eiken.....II-67
1$100
   OraSure Inks Multi-Year Purchase Contract with New York City.....II-68
Abbott Inks Single-Source Agreement with Novation for HIV Test.....II-68
Neogen Takes Over Centrus International.....II-68
Becton, Dickinson and Company Acquires GeneOhm Sciences.....II-68
1$100
   Inverness Medical Innovations Makes a Synergetic Purchase of ACON Laboratories.....II-69
Quest Diagnostics Strikes Deal with BD Diagnostics.....II-69
Novation Inks Pact with Abbott for Rapid HIV-1/2 Antibody Test.....II-69
TREK Diagnostic and Novation Inks Agreement.....II-69
Clinton Foundation Inks Agreement with Four Companies to Cut Prices.....II-69
Chembio Obtains FDA Approval for HIV 1/2 Stat-Pak and Sure Check HIV 1/2 Rapid Test
  PMAs.....II-69
1$100
   Roche’s LightCycler SeptiFast Test Attains CE Mark.....II-70
Zonda Expands Distribution of Products in Europe.....II-70
OraSure Wins Rapid HIV Tests Order.....II-70
MedMira Secures Orders for Rapid HIV Tests.....II-70
Cepheid Collaborates with Foundation for Innovative Diagnostics.....II-70
1$100
   Chembio Obtains Clearance for Rapid HIV Tests in Kenya.....II-71
Genesis Bioventures Bags US Patent for Rapid Prion- Detection Assay.....II-71
MedMira Obtains CE Mark for MiraCare.....II-71
Setema to Distribute Chembio’s Rapid HIV Tests in Ethiopia.....II-71
Clinton Foundation HIV/AIDS Initiative Selects Chembio to Provide Rapid HIV
  Tests.....II-71
Quidel Acquires immunochemical Fecal Occult Blood Test.....II-71
Xact Aid Snaps Up STD Alert.....II-71
1$100
   Grant Life Sciences Acquires Rapid Tests from AccuDx.....II-72
Millipore Ties Up with Gen-Probe.....II-72
Foundation for Innovative New Diagnostics forms Collaboration with Eiken
  Chemical.....II-72
WayPoint and Global Rapid Diagnostic Leader Enter into an Agreement.....II-72
Akers Biosciences Enters into a Distribution Agreement with Alco Industries.....II-72
Celsis and BioVentures Enter into Licensing Agreement.....II-72
1$100
   Thermo Electron Inks Pact with Genomic Profiling Systems.....II-73
Abbott and OraSure Enters into Agreement for OraQuick ADVANCE Rapid HIV-1/2
  Test.....II-73
bioMérieux Signs Agreement with Novel Diagnostics.....II-73
Dade Behring Bags FDA Approval for Antimicrobial Susceptibility Test Panels.....II-73
OraSure Bags HCV Patent License from Chiron and Ortho- Clinical Diagnostics.....II-73
1$100
   BD Diagnostics Receives FDA Approval for BD Directigen™ EZ Flu A+B Test.....II-74
BD Diagnostics Bags FDA Clearance for BBL™ CHROMagar™ MRSA Product.....II-74
MedMira Obtains Rights to Market Rapid HIV Tests in Guizhou Province, China.....II-74
Gen-Probe Obtains FDA Clearance for PROCLEIX® West Nile Virus Assay.....II-74
Medical Services International Secures Clearance for Rapid Test Kits.....II-74
Medical Services International Receives Exclusive Marketing Rights for TB Test
  Kit.....II-74
Adaltis Receives Orders for HIV Rapid Tests from China.....II-74
MedCap Bags Exclusive Distribution Rights for Syphilis Rapid Test.....II-74
1$100
   Genomic Profiling Systems Obtains NIAID Funds to Develop Testing Platform.....II-75
Gen-Probe Obtains US Patent for Automated Process for Nucleic Acid Testing.....II-75
Bio-Rad Receives Approval for HIV-1/HIV-2 Rapid Test.....II-75
Cambrex Makes a Synergetic Purchase of Genolife.....II-75
Cambrex Bioproducts Acquires Worldwide License from Epoch Biosciences.....II-75
1$100
   Cambrex Forges Licensing Agreement with John Hopkins University.....II-76
Calypte Biomedical and Adaltis Enters into an Agreement.....II-76
Calypte Biomedical Signs MoU with Pacific Biotech.....II-76
GlaxoSmithKline Process Employing Pall Rapid Test Receives FDA Approval.....II-76
Binax Receives FDA Approval for NOW Influenza A & B Rapid Test.....II-76
Spectral Diagnostics and IDx Inc. Announce US$12 Million R&D Project.....II-76
1$100
   Genome Therapeutics Transfers Streptococcus Pneumoniae Patent to Aventis.....II-77
Abbott Inks an Agreement with BioGenex Laboratories.....II-77
Bio-Rad and Enzon Announce Marketing Agreement.....II-77
bioMérieux and Omnimed Join Forces to Fight Against AIDS .....II-77
1$100
  8. Focus on Select Global Players.....II-788 $500  
   Abbott Laboratories (USA).....II-78
Abbott Diagnostics (USA).....II-78
Becton Dickinson and Company (USA).....II-78
1$100
   bioMerieux (France).....II-79
bioMerieux, Inc. (USA).....II-79
Bio-Rad Laboratories (USA).....II-79
1$100
   Cellabs Pty Ltd (Australia).....II-80
Celsis International Plc (UK).....II-80
Coris BioConcept (Belgium).....II-80
1$100
   F. Hoffmann-La Roche Ltd. (Switzerland).....II-81
Gen-Probe Incorporated (USA).....II-81
Genzyme Diagnostics (USA).....II-81
1$100
   Inverness Medical Innovations, Inc. (USA).....II-82
Unipath Limited (UK).....II-82
MedMira Inc. (Canada).....II-82
1$100
   Meridian Biosciences, Inc. (USA).....II-83
Orasure Technologies, Inc. (USA).....II-83
Orion Diagnostica Oy (Finland).....II-83
1$100
   Quidel Corporation (USA).....II-84
Siemens Medical Solutions Diagnostics (USA).....II-84
1$100
   Thermo Fisher Scientific, Inc. (USA).....II-85
Remel, Inc. (USA) .....II-85
Oxoid Limited (UK).....II-85
1$100
  9. Global Market Perspective.....II-86   
   Table 2: World Recent Past, Current & Future Market Analysis for Automated and Rapid Microbiological Tests by Geographic Region – US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-861$300
   Table 3: World Long-term Projections for Automated and Rapid Microbiological Tests by Geographic Region – US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-871$300
   Table 4: World 10-Year Perspective for Automated and Rapid Microbiological Tests by Geographic Region – Percentage Breakdown of Revenues for US, Europe, and Rest of World for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-881$300
   Table 5: World Recent Past, Current & Future Market Analysis for Automated and Rapid Microbiological Tests in Clinical Applications by Geographic Region – US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2000 through 2010 (includescorresponding Graph/Chart).....II-891$300
   Table 6: World Long-term Projections for Automated and Rapid Microbiological Tests in Clinical Applications by Geographic Region – US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-901$300
   Table 7: World Recent Past, Current & Future Market Analysis for Automated and Rapid Microbiological Tests in Clinical Applications by Equipment Used – Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems,Streptococcal Infection Rapid Tests, GC/Chlamydia RapidTests and Other Automated & Rapid Microbiological Tests Independently Analyzed with Annual Revenues in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-911$300
   Table 8: World Long-term Projections for Automated and Rapid Microbiological Tests in Clinical Applications by Equipment Used – Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia RapidTests and Other Automated & Rapid Microbiological Tests IndependentlyAnalyzed with Annual Revenues in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-921$300
   Table 9: World 10-Year Perspective for Automated and Rapid Microbiological Tests in Clinical Applicationsby Geographic Region – Percentage Breakdown of Revenues for US, Europe, and Rest of World forYears 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-931$300
   Table 10: World 10-Year Perspective for Automated and Rapid Microbiological Tests in Clinical Applications by Equipment Used – Percentage Breakdown of Revenues for Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia RapidTests and Other Automated & Rapid Microbiological Tests for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-941$300
   Table 11: World Recent Past, Current & Future Market Analysis for Automated Identification & Susceptibility Systems in Clinical Applications by Geographic Region – US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-951$300
   Table 12: World Long-term Projections for Automated and Rapid Microbiological Tests in Clinical Applications by Equipment Used – Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia RapidTests and Other Automated & Rapid Microbiological Tests IndependentlyAnalyzed with Annual Revenues in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-961$300
   Table 13: World 10-Year Perspective for Automated Identification & Susceptibility Systems in Clinical Applications by Geographic Region – Percentage Breakdown of Revenues for US, Europe, and Rest of World for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-971$300
   Table 14: World Recent Past, Current & Future Market Analysis for Automated Blood Culture Systems in Clinical Applications by Geographic Region – US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-981$300
   Table 15: World Long-term Projections for Automated Blood Culture Systems in Clinical Applications by Geographic Region – US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-991$300
   Table 16: World 10-Year Perspective for Automated Blood Culture Systems in Clinical Applications by Geographic Region – Percentage Breakdown of Revenues for US, Europe, and Rest of World for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-1001$300
   Table 17: World Recent Past, Current & Future Market Analysis for Automated Tuberculosis Systems in Clinical Applications by Geographic Region – US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-1011$300
   Table 18: World Long-term Projections for Automated Tuberculosis Systems in Clinical Applications by Geographic Region – US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-1021$300
   Table 19: World 10-Year Perspective for Automated Tuberculosis Systems in Clinical Applications by Geographic Region – Percentage Breakdown of Revenues for US, Europe, and Rest of World for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-1031$300
   Table 20: World Recent Past, Current & Future Market Analysis for Streptococcal Infection Rapid Tests in Clinical Applications by Geographic Region – US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-1041$300
   Table 21: World Long-term Projections for Streptococcal Infection Rapid Tests in Clinical Applications by Geographic Region – US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-1051$300
   Table 22: World 10-Year Perspective for Streptococcal Infection Rapid Tests in Clinical Applications by Geographic Region – Percentage Breakdown of Revenues for US, Europe, and Rest of World for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-1061$300
   Table 23: World Recent Past, Current & Future Market Analysis for GC/Chlamydia Rapid Tests in Clinical Applications by Geographic Region – US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-1071$300
   Table 24: World Long-term Projections for GC/Chlamydia RapidTests (*) in Clinical Applications by Geographic Region – US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-1081$300
   Table 25: World 10-Year Perspective for GC/Chlamydia Rapid Tests in Clinical Applications by Geographic Region – Percentage Breakdown of Revenues for US, Europe, and Rest of World for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-1091$300
   Table 26: World Recent Past, Current & Future Market Analysis for Other Automated & Rapid Microbiological Tests in Clinical Applications by Geographic Region – US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2000 through 2010(includes corresponding Graph/Chart).....II-1101$300
   Table 27: World Long-term Projections for Other Automated & Rapid Microbiological Tests in Clinical Applications by Geographic Region – US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-1111$300
   Table 28: World 10-Year Perspective for Other Automated & Rapid Microbiological Tests in Clinical Applications by Geographic Region – Percentage Breakdown of Revenues for US, Europe, and Rest of World for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-1121$300
   Table 29: World Recent Past, Current & Future Market Analysis for Automated and Rapid Microbiological Tests in Non-Clinical Applications by Geographic Region – US,Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-1131$300
   Table 30: World Long-term Projections for Automated and Rapid Microbiological Tests in Non-Clinical Applications by Geographic Region – US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-1141$300
   Table 31: World 10-Year Perspective for Automated and Rapid Microbiological Tests in Non-Clinical Applications by Geographic Region – Percentage Breakdown of Revenues for US, Europe, and Rest of World for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-1151$300
III. MARKET103$1950
  1. The United States.....III-141 $1675  
   A. Market Analysis.....III-1
A Current & Future Analysis .....III-1
Rapid Microbiology Tests - A Competitive Profile III-1 Consolidation in the Automated and Rapid Microbiological Tests Market.....III-1
Bioterrorism Tests – Gaining Prominence.....III-1
1$75
   Tracking Trends Across Product Segments.....III-2
STD Rapid Tests.....III-2
Market Share Trends of Leading Players:.....III-2
Table 32: Leading Players in the US Market for GC/Chlamydia Rapid Tests (2004 & 2005) - Percentage Breakdown of Value Sales by Company for Gen-Probe, Abbott, Becton Dickinson and Roche (includes corresponding Graph/Chart).....III-2
1$150
   Table 33: Leading Players in the US Market for Chlamydia Rapid Tests (2004 & 2005) - Percentage Breakdown of Value Sales by Company for Thermo Electron, Wampole / Inverness Medical Innovations, and Quidel (includes corresponding Graph/Chart).....III-3

Table 34: Leading Players in the US Market for Syphilis Rapid Tests (2004 & 2005) - Percentage Breakdown of Value Sales by Company for Becton Dickinson, Wampole/Inverness Medical Innovations, and Others (includes corresponding Graph/Chart) .....III-3
1$150
   Leading Players in HIV Rapid Testing Market.....III-4
Gastrointestinal Rapid Tests.....III-4
Market Share Trends of Leading Players.....III-4
Table 35: Leading Players in the US Market for C. Difficile Rapid Tests (2004 & 2005) -Percentage Breakdown of Value Sales by Company for Wampole/Inverness Medical Innovations, Meridian Biosciences, BioSite, Becton Dickinson, Thermo Electron, and Others (includes corresponding Graph/Chart).....III-4
1$150
   Table 36: Leading Players in the US Market for Cryptosporidium Rapid Tests (2004 & 2005) - Percentage Breakdown of Value Sales by Company for Remel, Meridian Biosciences, and Becton Dickinson (includes correspondingGraph/Chart).....III-5

Table 37: Leading Players in the US Market for Rotavirus Rapid Tests (2004 & 2005) - Percentage Breakdown of Value Sales by Company for Meridian Biosciences, FisherScientific, and Others (includes corresponding Graph/Chart).....III-5
1$150
   Table 38: Leading Players in the US Market for Giardia Rapid Tests (2004 & 2005) - Percentage Breakdown of Value Sales by Company for Remel, Meridian Biosciences, and Becton Dickinson (includes corresponding Graph/Chart).....III-6
Respiratory Rapid Tests.....III-6
Competition:.....III-6
1$150
   Table 39: Leading Players in the US Market for Influenza Rapid Tests (2004 & 2005) - Percentage Breakdown of Value Sales by Company for Quidel, Becton Dickinson, Thermo Electron, Binax and Others (includes corresponding Graph/Chart).....III-7

Table 40: Leading Players in the US Market for RSV Rapid Tests (2004 & 2005) - Percentage Breakdown of Value Sales by Company for Becton Dickinson, Binax, Thermo Electron and Others (includes corresponding Graph/Chart).....III-7
1$150
   Table 41: Leading Players in the US Market for Tuberculosis Rapid Tests (2004 & 2005) - Percentage Breakdown of Value Sales by Company for Gen-Probe, and Becton Dickinson.....III-8

Table 42: Leading Players in the US Market for M. Pneumoniae Rapid Tests (2004 & 2005) - Percentage Breakdown of Value Sales by Company for Meridian Biosciences, and Remel, Inc......III-8

Table 43: Leading Players in the US Market for Mononucleosis Rapid Tests (2004 & 2005) - Percentage Breakdown of Value Sales by Company for Wampole, Remel, Quidel, Thermo Electronand Others (includes corresponding Graph/Chart).....III-8
1$150
   Streptococcus Infection Rapid Tests.....III-9
Table 44: Leading Players in the US Market for Streptococcus A Rapid Tests (2004 & 2005) -Percentage Breakdown of Value Sales by Company for Quidel, Thermo Electron, Becton Dickinson, Genzyme and Others (includes corresponding Graph/Chart).....III-9
1$150
   Average Prices.....III-10
Table 45: Average Costs for Rapid Tests in the US (includes corresponding Graph/Chart).....III-10
A Peek into the Testing Practices of the US Food Industry.....III-10
1$150
   Table 46: Microbiology Tests in the US Food Industry by Sector: 2001 (includes corresponding Graph/Chart).....III-11
Product Innovations/Introductions.....III-11
7$725
   Strategic Corporate Developments.....III-1813$650
   Focus on Key Players.....III-31
Abbott Laboratories.....III-31
Abbott Diagnostics.....III-31
1$75
   Arlington Scientific, Inc......III-32
Becton Dickinson And Company.....III-32
bioMerieux, Inc......III-32
Bio-Rad Laboratories.....III-32
1$75
   Gen-Probe Incorporated.....III-33
Genzyme Diagnostics.....III-33
Inverness Medical Innovations, Inc.....III-33
1$75
   Meridian Biosciences, Inc......III-34
Orasure Technologies, Inc......III-34
1$75
   Quidel Corporation.....III-35
Remel Inc......III-35
Siemens Healthcare Diagnostics .....III-35
1$75
   B. Market Analytics.....III-36
Table 47: US Recent Past, Current & Future Market Analysis for Automated & Rapid Microbiological Tests by End-Use Segment – Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-36
1$150
   Table 48: US Long-term Projections for Automated & Rapid Microbiological Tests by End-Use Segment – Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-371$150
   Table 49: US 10-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Segment – Percentage Breakdown of Revenues for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, C/Chlamydia Rapid Tests, and Other Automated & Rapid MicrobiologicalTests) and Non-Clinical Applications for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-381$150
   Table 50: US Recent Past, Current & Future Market Analysis for Rapid Microbiological Tests by End-Use Segment – Clinical Applications (Streptococcus Infection Rapid Tests {Streptococcus A, and Streptococcus B}, STD Rapid Tests {GC/Chlamydia, HIV, and Syphilis}, Respiratory Rapid Tests {RSV, Mononucleosis, Tuberculosis, Mycoplasma Pneumoniae, Legionella, and Influenza} and Gastrointestinal Rapid Tests {Cryptosporidium, Giardia, Rotavirus, C. Difficile, and H. Pylori}) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-391$150
   Table 51: US Long-term Projections for Rapid Microbiological Tests by End-Use Segment – Clinical Applications (Streptococcus Infection Rapid Tests {Streptococcus A, and Streptococcus B}, STD Rapid Tests {GC/Chlamydia, HIV, and Syphilis}, Respiratory Rapid Tests {RSV, Mononucleosis, Tuberculosis, Mycoplasma Pneumoniae, Legionella, and Influenza} and Gastrointestinal Rapid Tests {Cryptosporidium, Giardia, Rotavirus, C. Difficile, and H. Pylori}) and Non-Clinical Applications IndependentlyAnalyzed with Annual Revenues in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-401$150
   Table 52: US 10-Year Perspective for Rapid Microbiological Tests by End-Use Segment – Percentage Breakdown of Revenues for Clinical Applications (Streptococcus Infection Rapid Tests {Streptococcus A, and Streptococcus B}, STD Rapid Tests {GC/Chlamydia, HIV, and Syphilis}, Respiratory Rapid Tests {RSV, Mononucleosis, Tuberculosis, Mycoplasma Pneumoniae, Legionella, and Influenza} and Gastrointestinal Rapid Tests {Cryptosporidium, Giardia, Rotavirus, C. Difficile, and H. Pylori}) and Non-Clinical Applications for2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-41
1$150
  2. Europe.....III-4211 $975  
   A. Market Analysis.....III-42
A Current & Future Analysis.....III-42
European Market Primer.....III-42
What Drives the Requirement Patterns of End-Users?.....III-42
Competitive Profile .....III-42
1$75
   Table 53: Leading Players in European Market for Automated & Rapid Microbiological Tests (2000) - Percentage Breakdown of Value Sales by Company for bioMerieux, Becton Dickinson, Organon Teknika, Merlin, Abbott, Dade, Unipath, and Others(includes corresponding Graph/Chart).....III-43
Trends & Issues.....III-43
Proliferation of Automated, and Rapid Tests in Europe .....III-43
1$150
   European Automated Market.....III-44
Probe Tests: “A Crack in the Future of Rapid Tests”.....III-44
Trends Across Product Segments.....III-44
GC/Chlamydia Rapid Tests.....III-44
Streptococcal Infection (Strep A) Rapid Tests.....III-44
1$75
   Automated Tuberculosis Systems Market.....III-45
Historic Competitive Profile .....III-45
Table 54: Leading Players in European Market for Chlamydia Rapid Tests (2000) - Percentage Breakdown of Value Sales by Company for Abbott, Oxoid, Unipath, Quidel, and Others (includes corresponding Graph/Chart).....III-45

Table 55: Leading Players in European Market for Streptococcal Infection (Strep A) Rapid Tests (2000) - Percentage Breakdown of Value Sales by Company for Abbott, Unipath, Quidel, Orion Diagnostics, Oxoid, and Becton Dickinson (includes corresponding Graph/Chart).....III-45

Table 56: Leading Players in European Market for Automated Blood Culture Systems (2000) - Percentage Breakdown of Value Sales by Company for Becton Dickinson, Organon Teknika, and bioMerieux (includes corresponding Graph/Chart).....III-45
1$150
   Product Innovations/Introductions.....III-461$75
   B. Market Analytics.....III-47
Table 57: European Recent Past, Current & Future Market Analysis for Automated & Rapid Microbiological Tests by Geographic Region – France, Germany, The United Kingdom, Italy, Spain, Russia, & Rest of Europe Independently Analyzed with Annual Revenuesin US$ Million for Years 2000 through 2010(includes corresponding Graph/Chart).....III-47
1$150
   Table 58: European Long-term Projections for Automated &Rapid Microbiological Tests by Geographic Region – France, Germany, The United Kingdom, Italy, Spain, Russia, & Rest of Europe Independently Analyzed withAnnual Revenues in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-481$150
   Table 59: European Recent Past, Current & Future Market Analysis for Automated & Rapid Microbiological Tests by End-Use Segment – Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-491$150
   Table 60: European Recent Past, Current & Future Market Analysis for Automated & Rapid Microbiological Tests by End-Use Segment – Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests,and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-501$150
   Table 61: European 10-Year Perspective for Automated & Rapid Microbiological Tests by Geographic Region – Percentage Breakdown of Revenues for France, Germany, The United Kingdom, Italy, Spain, Russia, & Rest of Europe for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-511$150
   Table 62: European 10-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Segment – Percentage Breakdown of Revenues for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal InfectionRapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-52
1$150
  2a. France.....III-538 $650  
   A. Market Analysis.....III-53
A Current & Future Analysis.....III-53
Leading Players in Select Segments –Historic Data.....III-53
Table 63: Leading Players in French Market for Automated & Rapid Microbiological Tests (2000) - Percentage Breakdown of Value Sales by Company for bioMerieux, Becton Dickinson, Merlin, Organon Teknika, Dade, Pasteur Sanofi Diagnostic, Oxoid and Abbott (includes corresponding Graph/Chart).....III-53
Chlamydia Rapid Tests.....III-53
Table 64: Leading Players in French Market for Chlamydia Rapid Tests (2000) – Percentage Breakdown of Value Salesby Company for Oxoid and Others.....III-53
1$150
   Automated Tuberculosis Systems.....III-54
Table 65: Leading Players in French Market for Automated Tuberculosis Systems (2000) - Percentage Breakdown of Value Sales by Company for Becton Dickinson and Others.....III-54
Automated Blood Culture Systems.....III-54
Table 66: Leading Players in French Market for Automated Blood Culture Systems (2000) - Percentage Breakdown of Value Sales by Company for Becton Dickinson, Organon Teknika, bioMerieux, and Pasteur Sanofi Diagnostic (includes corresponding Graph/Chart).....III-54
Automated Identification and Susceptibility Systems.....III-54
Table 67: Leading Players in French Market for Automated Identification and Susceptibility Systems (2000) - Percentage Breakdown of Value Sales by Company for bioMerieux, Merlin, Dade, and Becton Dickinson (includes corresponding Graph/Chart).....III-54
bioMerieux: A Key Player.....III-54
1$150
   Product Innovations/Introductions.....III-551$75
   Strategic Corporate Developments.....III-562$150
   B. Market Analytics.....III-58
Table 68: French Recent Past, Current & Future Market Analysis for Automated & Rapid Microbiological Tests by End-Use Segment – Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-58
1$150
   Table 69: French Long-term Projections for Automated & Rapid Microbiological Tests by End-Use Segment – Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-591$150
   Table 70: French 10-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Segment – Percentage Breakdown of Revenues for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-60
1$150
  2b. Germany.....III-616 $625  
   A. Market Analysis.....III-61
A Current & Future Analysis.....III-61
Competitive Structure .....III-61
Leading Players in Select Segments – Historic Data.....III-61
Table 71: Leading Players in German Market for Automated & Rapid Microbiological Tests (2000) - Percentage Breakdown of Value Sales by Company for bioMérieux, Organon Teknika, Becton Dickinson,Merlin, Abbott, Unipath, and Others (includes corresponding Graph/Chart).....III-61
1$150
   Streptococcal Infection Rapid Tests.....III-62
Table 72: Leading Players in German Market for Streptococcal Infection Rapid Tests (2000) Percentage Breakdown of Value Sales by Company for Abbott, Unipath and Quidel (includes corresponding Graph/Chart).....III-62
Automated Tuberculosis System.....III-62
Table 73: Leading Players in German Market for Automated Tuberculosis Systems (2000) - Percentage Breakdown of Value Sales by Company for Becton Dickinsonand Others.....III-62
Automated Blood Culture Systems.....III-62
Table 74: Leading Players in German Market for Automated Blood Culture Systems (2000) - Percentage Breakdown of Value Sales by Company for bioMerieux, Becton Dickinson, and Organon Teknika (includes corresponding Graph/Chart).....III-62
1$150
   Chlamydia Rapid Tests.....III-63
Table 75: Leading Players in German Market for Chlamydia Rapid Tests (2000) – Percentage Breakdown of Value Sales by Company for Abbott, Unipath, Quidel, Orgenics and International Microbio (includes corresponding Graph/Chart).....III-63
Automated Identification and Susceptibility Systems.....III-63
Table 76: Leading Players in German Market for Automated Identification and Susceptibility Systems (2000) - Percentage Breakdown of Value Sales by Company for bioMérieux, Merlin and Dade (includes corresponding Graph/Chart).....III-63
1$150
   Merlin Diagnostica GmbH – A Key Player.....III-64
B. Market Analytics.....III-64
Table 77: German Recent Past, Current & Future Market Analysis for Automated & Rapid Microbiological Tests by End-Use Segment – Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2000 through 2010 (includescorresponding Graph/Chart).....III-64
1$150
   Table 78: German Long-term Projections for Automated & Rapid Microbiological Tests by End-Use Segment – Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-651$150
   Table 79: German 10-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Segment – Percentage Breakdown of Revenues for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection RapidTests, GC/Chlamydia Rapid Tests, and OtherAutomated & Rapid Microbiological Tests) and Non-Clinical Applications for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-66
1$150
  2c. The United Kingdom.....III-6710 $850  
   A. Market Analysis.....III-67
A Current & Future Analysis .....III-67
Increasing Incidence of MRSA Spur Growth in Rapid Diagnostics.....III-67
Leading Players in Select Segments – Historic Data.....III-67
Table 80: Leading Players in the UK Market for Automated & Rapid Microbiological Tests (2000) - Percentage Breakdown of Value Sales by Company for bioMérieux, Becton Dickinson, Organon Teknika, Unipath, Abbott, and Others (includes corresponding Graph/Chart).....III-67
1$150
   Chlamydia Rapid Tests.....III-68
Table 81: Leading Players in the UK Market for Chlamydia Rapid Tests (2000)) - Percentage Breakdown of Value Sales by Company for Abbott, Unipath, Quidel, Orgenics and International Microbio (includes corresponding Graph/Chart).....III-68
Automated Tuberculosis System.....III-68
Table 82: Leading Players in the UK Market for Automated Tuberculosis Systems (2000) - Percentage Breakdown of Value Sales by Company for Becton Dickinson, and Others.....III-68
Automated Identification and Susceptibility Systems.....III-68
Table 83: Leading Players in the UK Marketfor Automated Identification and Susceptibility Systems (2000 & 2004) – Percentage Breakdown of Value Sales by Company for bioMerieux, and Becton Dickinson.....III-68
Streptococcal Infection Rapid Tests.....III-68
Table 84: Leading Players in the UK Market for Streptococcal Infection Rapid Tests (2000) - Percentage Breakdown of Value Sales by Company for Unipath and Abbott.....III-68
1$150
   Automated Blood Culture Systems.....III-69
Table 85: Leading Players in the UK Market for Automated Blood Culture Systems (2000) – Percentage Breakdown of Value Sales by Company for Becton Dickinson, Organon Teknika, and bioMerieux (includes corresponding Graph/Chart).....III-69
Product Innovation/Introduction.....III-69
2$300
   Strategic Corporate Developments.....III-712$150
   Focus on Select Players.....III-73
Celsis International Plc.....III-73
1$75
   Oxoid Limited.....III-74
B. Market Analytics.....III-74
Table 86: UK Recent Past, Current & Future Market Analysis for Automated & Rapid Microbiological Tests by End-Use Segment – Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-74
1$150
   Table 87: UK Long-term Projections for Automated & Rapid Microbiological Tests by End-Use Segment – Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-751$150
   Table 88: UK 10-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Segment – Percentage Breakdown of Revenues for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests,GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-ClinicalApplications for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-76
1$150
  2d. Italy.....III-775 $525  
   A. Market Analysis.....III-77
A Current & Future Analysis .....III-77
Leading Players in Select Segments-- Historic Data.....III-77
Table 89: Leading Players in Italian Market for Automated & Rapid Microbiological Tests (2000) - Percentage Breakdown of Value Sales by Company for Becton Dickinson, bioMerieux, OrganonTeknika, Dade, Abbott, Unipath, and Quidel (includes corresponding Graph/Chart).....III-77
1$150
   Streptococcal Infection Rapid Tests.....III-78
Table 90: Leading Players in Italian Market for Streptococcal Infection Rapid Tests (2000) - Percentage Breakdown of Value Sales by Company for Abbott, Unipath, Becton Dickinson and Quidel (includes corresponding Graph/Chart).....III-78
Automated Tuberculosis System.....III-78
Table 91: Leading Players in Italian Market for Automated Tuberculosis Systems (2000) - Percentage Breakdown of Value Sales by Company for Becton Dickinson, and Others.....III-78
Chlamydia Rapid Tests.....III-78
Table 92: Leading Players in Italian Market for Chlamydia Rapid Tests (2000) - Percentage Breakdownof Value Sales by Company for Unipath, Abbott, and Biolife (includes corresponding Graph/Chart).....III-78
1$150
   B. Market Analytics.....III-79
Table 93: Italian Recent Past, Current & Future Market Analysis for Automated & Rapid MicrobiologicalTests by End-Use Segment – Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, AutomatedTuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-ClinicalApplications Independently Analyzed with AnnualRevenues in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-79
1$150
   Table 94: Italian Long-term Projections for Automated & Rapid Microbiological Tests by End-Use Segment – Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-801$150
   Table 95: Italian 10-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Segment – Percentage Breakdown of Revenues for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems,Automated Tuberculosis Systems, StreptococcalInfection Rapid Tests, GC/Chlamydia Rapid Tests,and Other Automated & Rapid Microbiological Tests)and Non-Clinical Applications for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-81
1$150
  2e. Spain.....III-824 $425  
   A. Market Analysis.....III-82
A Current & Future Analysis .....III-82
Market Share Trends of Leading Players- Historic Data.....III-82
Table 96: Leading Players in Spanish Market for Automated Tuberculosis Systems (2000) - Percentage Breakdown of Value Sales by Company for bioMerieux, Organon Teknika, and Becton Dickinson (includes corresponding Graph/Chart).....III-82
1$150
   B. Market Analytics.....III-83
Table 97: Spanish Recent Past, Current & FutureMarket Analysis for Automated & Rapid Microbiological Tests by End-Use Segment – Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, AutomatedTuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-ClinicalApplications Independently Analyzed with Annual Revenues in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-83
1$150
   Table 98: Spanish Long-term Projections for Automated & Rapid Microbiological Tests by End-Use Segment – Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-841$150
   Table 99: Spanish 10-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Segment – Percentage Breakdown of Revenues for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal InfectionRapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-85
1$150
  2f. Russia.....III-863 $325  
   Market Analysis.....III-86
A Current & Future Analysis .....III-86
Table 100: Russian Recent Past, Current & Future Market Analysis for Automated & Rapid Microbiological Tests by End-Use Segment – Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, C/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-86
1$150
   Table 101: Russian Long-term Projections for Automated & Rapid Microbiological Tests by End-Use Segment – Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-871$150
   Table 102: Russian 10-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Segment – Percentage Breakdown of Revenues for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-88
1$150
  2g. Rest of Europe.....III-897 $575  
   A. Market Analysis.....III-89
A Current & Future Analysis .....III-89
Leading Players in Select Segments- Historic Data.....III-89
Streptococcal Infection Rapid Tests.....III-89
Table 103: Leading Players in Streptococcal Infection Rapid Tests Market in Rest of Europe (2000) - Percentage Breakdown of Value Sales by Company for Abbott, and Oxoid.....III-89
Automated Identification and Susceptibility Systems.....III-89
Table 104: Leading Players in Automated Identificationand Susceptibility Systems Market in Rest of Europe(2000) – Percentage Breakdown of Value Sales by Company for bioMerieux, and Becton Dickinson.....III-89
1$150
   Product Innovations/Introductions.....III-90
Strategic Corporate Developments.....III-90
2$150
   Focus on Select Players.....III-92
Coris BioConcept (Belgium).....III-92
F. Hoffmann-La Roche Ltd. (Switzerland).....III-92
Orion Diagnostica Oy (Finland).....III-92
1$75
   B. Market Analytics.....III-93
Table 105: Rest of Europe Recent Past, Current & Future Market Analysis for Automated & Rapid Microbiological Tests by End-Use Segment – Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-93
1$150
   Table 106: Rest of Europe Long-term Projections for Automated & Rapid Microbiological Tests by End-Use Segment – Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-941$150
   Table 107: Rest of Europe 10-Year Perspective for Automated & Rapid Microbiological Tests by Product Segment – Percentage Breakdown of Revenues for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-95
1$150
  3. Rest of World.....III-968 $825  
   A. Market Analysis.....III-96
A Current & Future Analysis .....III-96
Latin American Market.....III-96
Asia-Pacific – The Next Epicenter for the AIDS Epidemic........III-96
1$75
   Product Innovations/Introductions.....III-97
Strategic Corporate Developments.....III-97
3$225
   Focus on Select Players.....III-100
Cellabs Pty Ltd (Australia).....III-100
MedMira Inc. (Canada).....III-100
1$75
   B. Market Analytics.....III-101
Table 108: Rest of World Recent Past, Current & Future Market Analysis for Automated & Rapid Microbiological Tests by End-Use Segment – Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated &Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2000 through2010 (includes corresponding Graph/Chart).....III-101
1$150
   Table 109: Rest of World long-term Projections for Automated & Rapid Microbiological Tests by End-Use Segment – Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-1021$150
   Table 110: Rest of World 10-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Segment – Percentage Breakdown of Revenues for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated &Rapid Microbiological Tests) and Non-Clinical Applications for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-1031$150
IV. COMPETITIVE LANDSCAPE 377$995
  
Total Companies Profiled: 127 (including Divisions/Subsidiaries - 142)

Region/Country                 Players

The United States                 89
Canada                             3
Japan                              1
Europe                            40
     France                        5
     Germany                       5
     The United Kingdom           16
     Italy                         1
     Spain                         2
     Rest of Europe               11
Asia-Pacific (Excluding Japan)     7
Middle East                        2
Click here to request a full table of contents and more details on this project.		  
 
 
Due to the proprietary nature, our previews are offered only to manufacturers, top-tier management consultants, investment banks, and investment research groups.

© Copyrights 2010, Global Industry Analysts, Inc., USA.